Abstracts tagged "Co-morbidities"

Abstract Number: 1535 • 2015 ACR/ARHP Annual Meeting
The Clinical Impact of Overweight in Rheumatoid Arthritis Patients: Comparison Between Korean and Other Countries within the Comora Study
Kichul Shin¹, Eun Young Ahn², Hyun Mi Kwon², In Ah Choi³, Yeonsoo Baik⁴ and Yeong Wook Song², ¹Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ³Division of Rheumatology, Department of internal medicine, Chungbook National University Hospital, Cheongju-si, South Korea, ⁴Division of Rheumatology, Department of internal medicine, SMG-SNU Boramae Medical Center, Seoul, South Korea
Background/Purpose: Obesity has recently been spotlighted as an important comorbidity in rheumatoid arthritis (RA); not only associated with disease severity but also its development. Despite…
Abstract Number: 1698 • 2015 ACR/ARHP Annual Meeting
High Prevalence of Traditional Cardiovascular Risk Factors in an Ankylosing Spondylitis Cohort
Gillian Fitzgerald¹, Dara J Lundon², Phil Gallagher³, Claire Sheehy⁴, Catherine Sullivan⁵, Carmel Silke⁶, Frances Stafford⁷, Killian O Rourke⁸, Muhammad Haroon⁹, Ronan Mullan¹⁰, Oliver FitzGerald¹¹ and Finbar (Barry) O'Shea¹², ¹Rheumatology, St James's Hospital, Dublin 8, Ireland, ²School of Medicine, University College Dublin, Dublin, Ireland, ³Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴University Hospital Waterford, Waterford, Ireland, ⁵Rheumatology, UCHG Ireland, Galway, Ireland, ⁶Rheumatology, Sligo University Hospital, Sligo, Ireland, ⁷Rheumatology, Blackrock Clinic, Co Dublin, Ireland, ⁸Rheumatology, Midlands Regional Hospital, Tullamore, Co Offaly, Ireland, ⁹Rheumatology, Kerry General Hospital, Co Kerry, Ireland, ¹⁰Department of Rheumatology, Tallaght Hospital, TCD, Dublin 24, Ireland, ¹¹St Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin 4, Dublin 4, Ireland, ¹²Rheumatology Dept, St James's Hospital, Dublin, Ireland
Background/Purpose: Patients with Ankylosing Spondylitis (AS) have previously been considered an otherwise healthy patient population. However, emerging evidence suggests AS is an independent risk factor…
Abstract Number: 2325 • 2015 ACR/ARHP Annual Meeting
Quantitative Clues to Recognize and Document Comorbid Fibromyalgia in Routine Care of Patients with Other Rheumatic Diagnoses on a 10 Cm Distress Visual Analog Scale Found on 1-Page Physician Rheumetric Checklist
Kathryn A. Gibson¹, Katherine J. Bryant² and Theodore Pincus³, ¹Liverpool Hospital, Liverpool, Australia, ²University of New South Wales, Sydney, Australia, ³Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: A physician global estimate (DOCGL) is commonly used to assess patients with rheumatic diseases. Fibromyalgia (FM) has been reported as a comorbidity in 10-35%…
Abstract Number: 3162 • 2015 ACR/ARHP Annual Meeting
Prevalence of Chronic Comorbidities in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Systemic Lupus Erythematosus: An Analysis of UK Biobank Data
Eftychia Bellou¹, Michael Cook², John Bowes¹, Jamie C Sergeant³, Anne Barton⁴, Terence W. O'Neill² and Suzanne M.M. Verstappen², ¹Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁴The Kellgren Centre for Rheumatology, Central Manchester Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and systemic lupus erythematosus (SLE) are immune-mediated disorders and are associated with a number of…
Abstract Number: 3164 • 2015 ACR/ARHP Annual Meeting
Calcium Pyrophosphate Deposition Disease and Associated Medical Co-Morbidities in the Veteran Population
Crystal Kleiber Balderrama¹, Daniel S. Lans², Ann K. Rosenthal^1,3 and Christie M. Bartels⁴, ¹Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ²Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI, ³Division of Rheumatology, Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI, ⁴Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI
Title: Calcium Pyrophosphate Deposition Disease and Associated Medical Co-Morbidities in the Veteran Population. Background/Purpose: Precipitation of calcium pyrophosphate dihydrate (CPP) crystals in articular tissues…
Abstract Number: 3257 • 2015 ACR/ARHP Annual Meeting
The Link Between DAS28 and the Short-Term Risk of Acute Coronary Syndrome in RA, and Its Driving Factors
Lotta Ljung^1,2, Thomas Frisell³ and Johan Askling^3,4, ¹Department of Medicine, Solna, Clinical epidemiology unit, Karolinska Institutet, Stockholm, Sweden, ²Department for Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: The extent to which a short-term effect of the disease activity adds to the over-risk of coronary events in patients with Rheumatoid Arthritis (RA)…
Abstract Number: 43 • 2014 ACR/ARHP Annual Meeting
Deaths Associated with Ankylosing Spondylitis in France from 1969 to 2009
Clement Prati¹, Daniel Wendling² and Xavier Guillot³, ¹Rhumatologie, Hopital Jean Minjoz, Besancon, France, ²Service de Rhumatologie, CHU J Minjoz, Besancon, France, ³rheumatology, Besançon, France
Background/Purpose Ankylosing spondylitis (AS) is a chronic inflammatory joint disease that can lead to chronic pain in the axial and peripheral joints and to functional…
Abstract Number: 2442 • 2014 ACR/ARHP Annual Meeting
Aligning Ethics with Digital Health Technologies and Shared Decision-Making: Interview Accounts of Patients and Clinicians
Anne F. Townsend^1,2,3,4, Paul Adam⁵, Jenny Leese⁶, Linda C. Li^6,7, Michael McDonald², Sheila Kerr⁸, Gordon Whitehead⁸ and Catherine Backman^6,9, ¹Qualitative Research, Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Maurice Young Centre for Applied Ethics, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ³Occupational Science and Occupational Therapy, University of British Columbia, Vancouver, BC, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁷Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ⁸Arthritis Patient Advisory Board, Richmond, BC, Canada, ⁹Department of Occupational Science & Occupational Therapy, University of British Columbia, Vancouver, BC, Canada
Background/Purpose Medical ethics evolves as health care develops. Digital health technologies are transforming health care delivery and patient and clinician relationships. Ethical approaches are shifting…
Abstract Number: 2113 • 2014 ACR/ARHP Annual Meeting
The Number of Morbidities Drives the Health Care Expenditures and Presence of a Musculoskeletal Condition Is Additionally Accountable for Higher Costs
Antje van der Zee-Neuen¹, Polina Putrik², Sofia Ramiro³, Andras Keszei⁴, Astrid M. Chorus⁵, Rob de Bie⁶ and Annelies Boonen⁷, ¹Internal Medicine, Rheumatology, Maastricht University, Maastricht, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam & Hospital Garcia de Orta, Almada, Portugal, Amsterdam, Netherlands, ⁴Medical Informatics, RWTH Aachen University, Aachen, Germany, ⁵Netherlands Organization for Applied Scientific Research, Leiden, Netherlands, ⁶Epidemiology, Maastricht University, Maastricht, Netherlands, ⁷Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: In Europe, 70- 80% of all healthcare expenses are attributable to chronic diseases and a large part of these are musculoskeletal conditions (MSKC).Having >1…
Abstract Number: 1833 • 2014 ACR/ARHP Annual Meeting
Quality of Primary Care Management of Patients with and without Rheumatoid Arthritis (RA)
Jessica Widdifield¹, Claire Bombardier², Jacqueline Young¹, Noah Ivers³, R. Liisa Jaakkimainen⁴, Sasha Bernatsky⁵, J. Michael Paterson¹, J. Carter Thorne⁶, Pooneh S.Akhavan⁷, Debra Butt¹, Vandana Ahluwalia⁸ and Karen Tu¹, ¹Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁵Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁶Southlake Regional Health Centre, Newmarket, Newmarket, ON, Canada, ⁷Mount Sinai Hospital, Toronto, ON, Canada, ⁸William Osler Health Center, Brampton, ON, Canada
Background/Purpose: Little is known about the quality of care received by patients with multiple chronic conditions in primary care and whether quality care is different…
Abstract Number: 1844 • 2014 ACR/ARHP Annual Meeting
Identification of a Patient Phenotype Which Impacts Response to Therapy in Rheumatoid Arthritis Clinical Trials: Certolizumab Pegol Phase 4 Trial Data
Jeffrey R. Curtis¹, Melvin Churchill², Alan Kivitz³, Laura Gauer⁴, Christopher Herrem⁴, David Carter⁵, Jeffrey Melin⁴ and Yusuf Yazici⁶, ¹The University of Alabama at Birmingham, Birmingham, AL, ²Arthritis Center of Nebraska, Lincoln, NE, ³Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁴UCB Pharma, Smyrna, GA, ⁵UCB Pharma, Brussels, Belgium, ⁶New York University Hospital for Joint Diseases, New York, NY
Background/Purpose The PREDICT trial (NCT01255761) examined predictability of certolizumab pegol (CZP) treatment success at Week (Wk) 52 based on response at Wk12 assessed by RAPID3…
Abstract Number: 1428 • 2014 ACR/ARHP Annual Meeting
Comparison of Application of the European Society Cardiology, Adult Treatment Panel III, and ACC/AHA Guidelines for Cardiovascular Disease Prevention in a French Cohort of Rheumatoid Arthritis
Martin Soubrier¹, Zuzana Tatar², Maxime Chevreau³, Bruno Pereira⁴, Laure Gossec⁵, P Gaudin⁶ and Maxime Dougados⁷, ¹COMEDRA trial group, Paris, France, ²Centre Jean Perrin, Clermont Ferrand, France, ³Rheumatology, CHU Sud Hospital, Grenoble, France, ⁴Clinical research department, Clermont-Ferrand, France, ⁵Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d’Epidémiologie et de Santé Publique, paris, France, ⁶CHU Hôpital Sud, Grenoble, France, ⁷RAID working group for EULAR, Zurich, Switzerland
Background/Purpose Cardiovascular risk (CVR) is increased in RA and should be evaluated annually. EULAR recommends using the SCORE equation to calculate risk, after applying a…
Abstract Number: 1313 • 2014 ACR/ARHP Annual Meeting
Comorbidity Patterns in Children with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance Registry
Marc D. Natter¹, Mei-Sing Ong², Kenneth D. Mandl³, Laura Schanberg⁴, Yukiko Kimura⁵, Norman Ilowite⁶ and the CARRA Registry Investigators, ¹Intelligent Health Labs, Children's Hospital Boston, Boston, MA, ²Australian Institute of Health Innovation, University of New South Wales, Sydney, Australia, ³Intelligent Health Lab, Children's Hospital Boston, Boston, MA, ⁴Duke University, Durham, NC, ⁵Pediatric Rheumatology, Hackensack Univ Medical Ctr, Hackensack, NJ, ⁶Rheumatology, Children's Hospital Montefiore, Bronx, NY
Background/Purpose: Knowledge of co-occurring disease processes (comorbidities) is important for understanding disease pathogenesis, refining disease classifications, developing appropriate screening and prevention strategies, and determining overall…
Abstract Number: 553 • 2014 ACR/ARHP Annual Meeting
Comparison of Baseline Extra-Articular Manifestations, Comorbidities, and Long-Term Safety in Patients Treated with Adalimumab for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Joachim Sieper¹, Désirée van der Heijde², Nupun A. Varothai³ and Jaclyn K. Anderson³, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³AbbVie Inc., North Chicago, IL
Background/Purpose: To compare 1) extra-articular manifestations, 2) baseline comorbidities, and 3) adverse event (AE) rates with long-term adalimumab (ADA) therapy in patients (pts) treated in…
Abstract Number: 422 • 2014 ACR/ARHP Annual Meeting
Correlation of RAPID3, DAS28 and CDAI in Disease Activity and Effects of Education Level and Co-Morbid Diseases on This Assesment in RA
Kubilay Sahin¹, Yasar Karaaslan^2,3, Zeynep Ozbalkan¹, Ahmet Omma¹ and Nesibe Yesil¹, ¹Rheumatology, Ankara Numune Education and Research Hospital, Ankara, Turkey, ²Rheumatology, Hitit University, Corum, Turkey, ³Ankara Numune Training and Research Hospital, Ankara, Turkey
Background/Purpose RAPID3 is an activity index based on only the patient's report in RA. It doesn’t require joint counts and it isn’t time consuming. Therefore…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].